Development of TAK 700 for Prostate Cancer cancelled-Takeda

Takeda Pharmaceutical has announced that it has voluntarily decided to end the development program for TAK 700 (orteronel) for Prostate Cancer. The decision follows the results of two Phase III clinical trials in metastatic, castration resistant Prostate Cancer (mCRPC) which found while orteronel plus prednisone could extend the time patients lived before their cancer progressed, it did not extend overall survival in these patients.

After careful consideration of the data from these trials, the company has determined that the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC, given the availability of other therapies. The interim analysis of the ELM-PC5 trial did show an advantage for orteronel plus prednisone for the secondary endpoint, radiographic progression-free survival over the control arm. There were no significant safety concerns in either study. The drug's development has been cancelled in Japan, the US and the EU.